ID

33587

Description

Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01486251

Link

https://clinicaltrials.gov/show/NCT01486251

Keywords

Versions (1)
  1. 12/13/18 12/13/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

December 13, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Colorectal Carcinoma NCT01486251

English

Eligibility Colorectal Carcinoma NCT01486251

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with histologically confirmed diagnosis of crc
Description

Colorectal Carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0009402
measurable metastatic disease to the liver in proven disease progression (according to recist criteria) at baseline (within 4 weeks prior to study entry), with at least one lesion > 2cm considered appropriate for dce-us examination
Description

Secondary malignant neoplasm of liver Measurable | Disease Progression | Lesion Size Quantity | Lesion Appropriate Dynamic Contrast-Enhanced Ultrasound Imaging

Data type

boolean

Alias
UMLS CUI [1,1]
C0494165
UMLS CUI [1,2]
C1513040
UMLS CUI [2]
C0242656
UMLS CUI [3,1]
C0221198
UMLS CUI [3,2]
C0456389
UMLS CUI [3,3]
C1265611
UMLS CUI [4,1]
C0221198
UMLS CUI [4,2]
C1548787
UMLS CUI [4,3]
C3897003
previously exposed to at least, irinotecan, oxaliplatin and a fluoropyrimidine, all 3 administered at optimal doses, over one or two chemotherapy (ct) lines for metastatic disease with a clear resistance to these drugs. previous exposure to bevacizumab and/or anti-egfr monoclonal antibody is allowed.
Description

Exposure to Irinotecan Dose Optimum | Exposure to Oxaliplatin Dose Optimum | Exposure to Fluoropyrimidine Dose Optimum | Chemotherapy Regimen Quantity Neoplasm Metastasis | Drug resistance | Exposure to Bevacizumab | Exposure to Anti-EGFR Monoclonal Antibody

Data type

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C0123931
UMLS CUI [1,3]
C0178602
UMLS CUI [1,4]
C2698651
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C0069717
UMLS CUI [2,3]
C0178602
UMLS CUI [2,4]
C2698651
UMLS CUI [3,1]
C0332157
UMLS CUI [3,2]
C0596581
UMLS CUI [3,3]
C0178602
UMLS CUI [3,4]
C2698651
UMLS CUI [4,1]
C0392920
UMLS CUI [4,2]
C1265611
UMLS CUI [4,3]
C0027627
UMLS CUI [5]
C0013203
UMLS CUI [6,1]
C0332157
UMLS CUI [6,2]
C0796392
UMLS CUI [7,1]
C0332157
UMLS CUI [7,2]
C4522190
age ≥18 years; performance status (ps) 0-2 and life expectancy > 3 months.
Description

Age | Performance status | Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C1518965
UMLS CUI [3]
C0023671
adequate biological functions: neutrophils ≥ 1.5 x 109/l; platelets ≥ 100 x 109/l; hemoglobin > 9 g/dl; creatinine clearance > 30 ml/min (cockcroft & gault formula). serum bilirubin < 1,5 x the upper normal limit (unl) and ast/alt < 5 x unl.
Description

Biological functions | Neutrophil count | Platelet Count measurement | Hemoglobin measurement | Estimation of creatinine clearance by Cockcroft-Gault formula | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Data type

boolean

Alias
UMLS CUI [1]
C3714634
UMLS CUI [2]
C0200633
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0518015
UMLS CUI [5]
C2711451
UMLS CUI [6]
C1278039
UMLS CUI [7]
C0201899
UMLS CUI [8]
C0201836
signed written informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
female patients with childbearing potential (<2 years after last menstruation) and male must use effective means of contraception during the study treatment and at least 6 months after the last study drug administration.
Description

Childbearing Potential Contraceptive methods | Gender Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C0700589
Back to the top of the page

Similar models

Eligibility Colorectal Carcinoma NCT01486251

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Colorectal Carcinoma
Item
patients with histologically confirmed diagnosis of crc
boolean
C0009402 (UMLS CUI [1])
Secondary malignant neoplasm of liver Measurable | Disease Progression | Lesion Size Quantity | Lesion Appropriate Dynamic Contrast-Enhanced Ultrasound Imaging
Item
measurable metastatic disease to the liver in proven disease progression (according to recist criteria) at baseline (within 4 weeks prior to study entry), with at least one lesion > 2cm considered appropriate for dce-us examination
boolean
C0494165 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
C0221198 (UMLS CUI [3,1])
C0456389 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0221198 (UMLS CUI [4,1])
C1548787 (UMLS CUI [4,2])
C3897003 (UMLS CUI [4,3])
Exposure to Irinotecan Dose Optimum | Exposure to Oxaliplatin Dose Optimum | Exposure to Fluoropyrimidine Dose Optimum | Chemotherapy Regimen Quantity Neoplasm Metastasis | Drug resistance | Exposure to Bevacizumab | Exposure to Anti-EGFR Monoclonal Antibody
Item
previously exposed to at least, irinotecan, oxaliplatin and a fluoropyrimidine, all 3 administered at optimal doses, over one or two chemotherapy (ct) lines for metastatic disease with a clear resistance to these drugs. previous exposure to bevacizumab and/or anti-egfr monoclonal antibody is allowed.
boolean
C0332157 (UMLS CUI [1,1])
C0123931 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C2698651 (UMLS CUI [1,4])
C0332157 (UMLS CUI [2,1])
C0069717 (UMLS CUI [2,2])
C0178602 (UMLS CUI [2,3])
C2698651 (UMLS CUI [2,4])
C0332157 (UMLS CUI [3,1])
C0596581 (UMLS CUI [3,2])
C0178602 (UMLS CUI [3,3])
C2698651 (UMLS CUI [3,4])
C0392920 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0027627 (UMLS CUI [4,3])
C0013203 (UMLS CUI [5])
C0332157 (UMLS CUI [6,1])
C0796392 (UMLS CUI [6,2])
C0332157 (UMLS CUI [7,1])
C4522190 (UMLS CUI [7,2])
Age | Performance status | Life Expectancy
Item
age ≥18 years; performance status (ps) 0-2 and life expectancy > 3 months.
boolean
C0001779 (UMLS CUI [1])
C1518965 (UMLS CUI [2])
C0023671 (UMLS CUI [3])
Biological functions | Neutrophil count | Platelet Count measurement | Hemoglobin measurement | Estimation of creatinine clearance by Cockcroft-Gault formula | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
adequate biological functions: neutrophils ≥ 1.5 x 109/l; platelets ≥ 100 x 109/l; hemoglobin > 9 g/dl; creatinine clearance > 30 ml/min (cockcroft & gault formula). serum bilirubin < 1,5 x the upper normal limit (unl) and ast/alt < 5 x unl.
boolean
C3714634 (UMLS CUI [1])
C0200633 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0518015 (UMLS CUI [4])
C2711451 (UMLS CUI [5])
C1278039 (UMLS CUI [6])
C0201899 (UMLS CUI [7])
C0201836 (UMLS CUI [8])
Informed Consent
Item
signed written informed consent
boolean
C0021430 (UMLS CUI [1])
Childbearing Potential Contraceptive methods | Gender Contraceptive methods
Item
female patients with childbearing potential (<2 years after last menstruation) and male must use effective means of contraception during the study treatment and at least 6 months after the last study drug administration.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial